T. Rowe Price Investment Management
GLUE icon

T. Rowe Price Investment Management’s Monte Rosa Therapeutics GLUE Stock Holding History

T. Rowe Price Investment Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-21,364
Closed -$147K – 578
2023
Q2 		$147K Sell
21,364
-1,695,701
-99% -$11M ﹤0.01% 564
2023
Q1 		$13.4M Sell
1,717,065
-217,474
-11% -$1.51M 0.01% 500
2022
Q4 		$14.7M Buy
1,934,539
+9,761
+0.5% +$81.3K 0.01% 487
2022
Q3 		$15.7M Buy
+1,924,778
New +$17.7M 0.01% 473

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Investment Management's GLUE Position: Q3 2023 in Review

T. Rowe Price Investment Management sold out of Monte Rosa Therapeutics (GLUE) in Q3 2023, closing a stake of 21,364 shares — an estimated $147K sold.

T. Rowe Price Investment Management first reported a position in GLUE in Q3 2022 and held it in 4 quarters. The position peaked at $15.7M in Q3 2022. 71 funds tracked by Wall St. Rank hold GLUE as of Q3 2023.

  • T. Rowe Price Investment Management reported no remaining Monte Rosa Therapeutics position as of Q3 2023 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 21,364 Monte Rosa Therapeutics shares in Q3 2023, an estimated $147K.
  • T. Rowe Price Investment Management first reported a position in Monte Rosa Therapeutics in Q3 2022 and held it in 4 quarters.
  • T. Rowe Price Investment Management's Monte Rosa Therapeutics position peaked at $15.7M in Q3 2022.
  • 71 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2023.

Based on T. Rowe Price Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.